WO2003012048A3 - Antigens of and antibodies to translocated molecules of microorganisms and uses thereof - Google Patents

Antigens of and antibodies to translocated molecules of microorganisms and uses thereof Download PDF

Info

Publication number
WO2003012048A3
WO2003012048A3 PCT/US2002/024121 US0224121W WO03012048A3 WO 2003012048 A3 WO2003012048 A3 WO 2003012048A3 US 0224121 W US0224121 W US 0224121W WO 03012048 A3 WO03012048 A3 WO 03012048A3
Authority
WO
WIPO (PCT)
Prior art keywords
molecules
translocated
binding
antibodies
antigens
Prior art date
Application number
PCT/US2002/024121
Other languages
French (fr)
Other versions
WO2003012048A2 (en
Inventor
Joel B Baseman
Rene Alvarez
Thirumalai R Kannan
Original Assignee
Univ Texas
Joel B Baseman
Rene Alvarez
Thirumalai R Kannan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Joel B Baseman, Rene Alvarez, Thirumalai R Kannan filed Critical Univ Texas
Priority to US10/485,002 priority Critical patent/US20040241689A1/en
Priority to EP02765903A priority patent/EP1420820A4/en
Priority to CA002455038A priority patent/CA2455038A1/en
Publication of WO2003012048A2 publication Critical patent/WO2003012048A2/en
Publication of WO2003012048A3 publication Critical patent/WO2003012048A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
    • C12Y102/01051—Pyruvate dehydrogenase (NADP+) (1.2.1.51)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
    • C12Y102/05—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with a quinone or similar compound as acceptor (1.2.5)
    • C12Y102/05001—Pyruvate dehydrogenase (quinone) (1.2.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

This application describes intracellular, cytoplasmic molecules that are translocated to the surface of a microorganism and participate in binding the microorganism to the surface of a host cell. Examples of such translocated molecules include glycerahdehyde 3-phosphate dehydrogenase, pyruvate dehydrogenase, and elongation factor-Tu. Regions oftranslocated molecules important for binding, as well as molecules which disrupt binding, are described. Antibodies directed to translocated molecules are also described.
PCT/US2002/024121 2001-07-31 2002-07-30 Antigens of and antibodies to translocated molecules of microorganisms and uses thereof WO2003012048A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/485,002 US20040241689A1 (en) 2001-07-31 2002-07-30 Antigens of and antibodies to translocated molecules of microorganisms and uses thereof
EP02765903A EP1420820A4 (en) 2001-07-31 2002-07-30 Antigens of and antibodies to translocated molecules of microorganisms and uses thereof
CA002455038A CA2455038A1 (en) 2001-07-31 2002-07-30 Antigens of and antibodies to translocated molecules of microorganisms and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30912801P 2001-07-31 2001-07-31
US60/309,128 2001-07-31

Publications (2)

Publication Number Publication Date
WO2003012048A2 WO2003012048A2 (en) 2003-02-13
WO2003012048A3 true WO2003012048A3 (en) 2004-01-15

Family

ID=23196816

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/024121 WO2003012048A2 (en) 2001-07-31 2002-07-30 Antigens of and antibodies to translocated molecules of microorganisms and uses thereof

Country Status (4)

Country Link
US (1) US20040241689A1 (en)
EP (1) EP1420820A4 (en)
CA (1) CA2455038A1 (en)
WO (1) WO2003012048A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3037822B1 (en) * 2013-08-23 2019-10-09 Tauns Co., Ltd. Mycoplasma pneumoniae immunological detection method and kit
MX2018000963A (en) 2018-01-22 2018-12-13 Federico Amezcua Amezcua Synergistic pharmaceutical composition originated from the active enantiomer s-ketorolac tromethamine and tramadol hydrochloride.

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5308612A (en) * 1992-08-12 1994-05-03 Blue Marble Research, Inc. Uses of polystyrenesulfonate and related compounds as inhibitors of transactivating transcription factor (TAT) and as therapeutics for HIV infection and AIDS
US5576186A (en) * 1994-09-01 1996-11-19 The University Of Kansas Diagnosis and monitoring of rheumatological diseases by detection of anti-EF1-α antibodies
WO1997007216A1 (en) * 1995-08-19 1997-02-27 The Victoria University Of Manchester Deuteriated substances
US5637677A (en) * 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US5650432A (en) * 1995-03-24 1997-07-22 Jlb, Inc. Method of treating or preventing non-viral microbial infection
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
US5683674A (en) * 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
US5741489A (en) * 1996-05-24 1998-04-21 Anitox Corporation Passively administered antibody that enhances feed conversion efficiency
US5834423A (en) * 1994-07-15 1998-11-10 Taiyo Kagaku Co., Ltd. Pharmaceutical composition containing sialic acid derivatives
US5883079A (en) * 1992-07-31 1999-03-16 Neose Technologies, Inc. Method for inhibiting H. pylori infection in mammalian tissue
US5908837A (en) * 1991-05-02 1999-06-01 Yeda Research And Development Co. Ltd. Methods of using low molecular weight heparins for prevention or treatment of pathological processes
US6096521A (en) * 1995-09-22 2000-08-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Adhesin from Helicobacter pylori
WO2000045177A1 (en) * 1999-01-27 2000-08-03 Pharmacia & Upjohn Company Assays for modulators of elongation factor p activity
US6235709B1 (en) * 1998-12-11 2001-05-22 Ghen Corporation Inhibitor of helicobacter pylori colonization
US6235711B1 (en) * 1996-06-21 2001-05-22 Zeneca Limited Cell adhesion ihibiting compounds
US6268160B1 (en) * 1997-08-28 2001-07-31 Medical Research Council Method of screening for anti-malarial compounds
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US6406704B1 (en) * 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453489A (en) * 1992-01-31 1995-09-26 La Jolla Cancer Research Foundation Polypeptide fragments of fibronectin which can modulate extracellular matrix assembly
WO1999041270A1 (en) * 1998-02-11 1999-08-19 The Regents Of The University Of California Compositions and methods for the inhibition of muc-5 mucin gene expression

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683674A (en) * 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
US5637677A (en) * 1987-07-16 1997-06-10 The Trustees Of The University Of Pennsylvania Biologically active compounds and methods of constructing and using the same
US5908837A (en) * 1991-05-02 1999-06-01 Yeda Research And Development Co. Ltd. Methods of using low molecular weight heparins for prevention or treatment of pathological processes
US5883079A (en) * 1992-07-31 1999-03-16 Neose Technologies, Inc. Method for inhibiting H. pylori infection in mammalian tissue
US5308612A (en) * 1992-08-12 1994-05-03 Blue Marble Research, Inc. Uses of polystyrenesulfonate and related compounds as inhibitors of transactivating transcription factor (TAT) and as therapeutics for HIV infection and AIDS
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
US5834423A (en) * 1994-07-15 1998-11-10 Taiyo Kagaku Co., Ltd. Pharmaceutical composition containing sialic acid derivatives
US5576186A (en) * 1994-09-01 1996-11-19 The University Of Kansas Diagnosis and monitoring of rheumatological diseases by detection of anti-EF1-α antibodies
US5650432A (en) * 1995-03-24 1997-07-22 Jlb, Inc. Method of treating or preventing non-viral microbial infection
WO1997007216A1 (en) * 1995-08-19 1997-02-27 The Victoria University Of Manchester Deuteriated substances
US6096521A (en) * 1995-09-22 2000-08-01 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Adhesin from Helicobacter pylori
US5741489A (en) * 1996-05-24 1998-04-21 Anitox Corporation Passively administered antibody that enhances feed conversion efficiency
US6235711B1 (en) * 1996-06-21 2001-05-22 Zeneca Limited Cell adhesion ihibiting compounds
US6406704B1 (en) * 1996-08-29 2002-06-18 Genesis Research And Development Corporation Limited Compounds and methods for treatment and diagnosis of mycobacterial infections
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
US6268160B1 (en) * 1997-08-28 2001-07-31 Medical Research Council Method of screening for anti-malarial compounds
US6235709B1 (en) * 1998-12-11 2001-05-22 Ghen Corporation Inhibitor of helicobacter pylori colonization
WO2000045177A1 (en) * 1999-01-27 2000-08-03 Pharmacia & Upjohn Company Assays for modulators of elongation factor p activity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BISSWANGER H.: "Fluoropyruvate: A potent inhibitor of the bacterial and the mammalian pyruvate dehydrogenase complex", BIOCHEMICAL AND BIOPHYSIUCAL RESEARCH COMMUNICATIONS, vol. 95, no. 2, 31 July 1980 (1980-07-31), pages 513 - 519, XP002961160 *
CAPPELLANO ET AL.: "Natural kirromycin resistance of elongation factor Tu from the kirrothricin producer streptomyces cinnamoneus", MICROBIOLOGY, vol. 143, 1997, pages 617 - 624, XP002961157 *
MIKULIK ET AL.: "Sequencing of the Tuf1 gene and the phosphorylation pattern of EF-Tu1 during development and differentiation in streptomyces collinus producing kirromycin", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 213, no. 2, 15 August 1995 (1995-08-15), pages 454 - 461, XP002961159 *
MUKHOPADHYAY ET AL.: "Complex formation of the elongation factor Tu from pseudomonas aeruginosa with nucleoside diphosphate kinase modulates ribosomal GTP synthesis and peptide chain elongation", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, no. 28, 11 July 1997 (1997-07-11), pages 17815 - 17820, XP002961158 *
NEFELOVA ET AL.: "Antibiotic action of bacillus polymyxa 153 enzymatic activity", ANTIBIOTIKI (USSR), vol. 25, no. 2, February 1980 (1980-02-01), pages 117 - 121, XP002961161 *

Also Published As

Publication number Publication date
EP1420820A4 (en) 2005-04-06
EP1420820A2 (en) 2004-05-26
US20040241689A1 (en) 2004-12-02
CA2455038A1 (en) 2003-02-13
WO2003012048A2 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
WO2008013996A3 (en) Engineered microorganisms for increasing product yield in biotransformations, related methods and systems
WO2004029219A3 (en) Cell-based rna interference and related methods and compositions
EP2345671B8 (en) Optimized fc variants and methods for their generation
WO2007075891A3 (en) Multiplex assays using magnetic and non-magnetic particles
WO2002086083A3 (en) Methods of enhancing cell responsiveness
WO2006105361A3 (en) Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
WO2004099249A3 (en) Optimized fc variants and methods for their generation
WO2003093441A3 (en) A method of regulating gene expression
MXPA05002429A (en) Nanoparticles, method for modifying their surfaces, dispersion of nanoparticles, method for the production and the utilization thereof.
WO2008036060A3 (en) Clostridial toxin activity assays
WO2008054858A3 (en) Anionic fuel cells, hybrid fuel cells, and methods of fabrication thereof
WO2005087951A3 (en) Reagents, methods and kits for use in deactivating nucleic acids
WO2007051164A3 (en) Toll like receptor 3 modulators, methods and uses
WO2008091288A3 (en) Microbial synthesis of d-1,2,4-butanetriol
WO2005047545A3 (en) Microarray controls
WO2004090169A3 (en) Compositions for controlled release of enzymatic reaction components
WO2005123913A3 (en) Reversibly modified thermostable enzyme compositions and methods of making and using the same
WO2005046597A3 (en) Antibodies to cd44 glycoforms and uses thereof
AU2002952797A0 (en) Centrifugal device and method using same
AU2003302165A1 (en) Prostate specific antigens, conjugates thereof, methods for their preparation and uses thereof.
WO2003012048A3 (en) Antigens of and antibodies to translocated molecules of microorganisms and uses thereof
WO2005028621A3 (en) Assays with primary cells
AU2002368056A1 (en) Novel pla2 enzyme, it's antibody, enzyme inhibitor and use and the preparation methods thereof
WO2003034025A3 (en) Methods and reagents for improved cell-based assays
GB2430266A (en) Ionic assay medium

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2002329663

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2455038

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002765903

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002765903

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10485002

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP